Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
$50.18
$1.93(2.32%)
At close: 4:00 PM EST
$50.18
$1.93(2.32%)
Day’s Range― - ―
52-Week Range$43.08 - $109.88
Previous CloseN/A
Volume3.65M
Average Volume (3M)19.91M
Market Cap
$224.30B
Enterprise Value$257.56B
Total Cash (Recent Filing)$32.58B
Total Debt (Recent Filing)$101.21B
Price to Earnings (P/E)14.6
Beta1.12
Next Earnings
Feb 04, 2026EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend Yield3.67%
Share Statistics
EPS (TTM)0.70
Shares Outstanding3,390,128,000
10 Day Avg. Volume13,886,606
30 Day Avg. Volume19,912,860
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)19.23
Price to Sales (P/S)9.50
P/FCF Ratio39.62
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda1.57
Forecast
1Y Price Target
$55.28Price Target Upside10.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product LaunchNovo is planning to launch a discounted introductory self-pay offer for patients in the US, making their medications more affordable.
Regulatory ApprovalThe FDA's publication of a GLP-1 API 'Green List' is a mild regulatory win for Novo.
Strategic PartnershipsNovo's recent Medicare deal with the Trump administration shows efforts to regain footing in the obesity/metabolic market.
Bears Say
Financial PerformanceNovo Nordisk's 3Q25 results show a miss on the top and bottom line, influencing negative sentiment.
Market CompetitionLilly's Mounjaro & Zepbound are expected to continue to take incremental U.S. share from Ozempic and Wegovy.
Pricing ChallengesRecent net pricing declines for the GLP-1 portfolio have been accelerated, adding pressure on Novo Nordisk's financial performance.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $43.08 and its highest was $109.88 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $224.30B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Feb 04, 2026 which is in 50 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Nov 05, 2025. The company reported $0.698 earnings per share for the quarter, missing the consensus estimate of $0.764 by -$0.066.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.412 which represents an annual dividend yield of 3.67%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.91.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.698 in its last earnings report, missing expectations of $0.764. Following the earnings report the stock price went up 0.435%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$55.28 (10.16% Upside)
$55.28 (10.16% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.87%
12-Months-Change
Fundamentals
Return on Equity
68.30%
Trailing 12-Months
Asset Growth
35.53%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk is a global healthcare company based in Denmark, specializing in the development and manufacturing of pharmaceutical products. The company primarily focuses on diabetes care, obesity care, hemophilia care, and hormone replacement therapy. Novo Nordisk is a leader in diabetes treatments, offering a range of insulin products and GLP-1 receptor agonists, as well as therapies for other chronic conditions such as growth disorders and hemophilia.
NVO Company Deck
NVO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in sales and continued expansion in obesity care, supported by strategic acquisitions. However, significant challenges remain, including market share loss, restructuring efforts, and pricing pressures.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$55.28
▲(10.16% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.32% Mutual Funds
4.01% Other Institutional Investors
94.48% Public Companies and Individual Investors